Literature DB >> 2553466

Hepatitis A antibody in blood donors in North East Thames region: implications to prevention policies.

N J Scott1, J F Harrison, A J Zuckerman.   

Abstract

A total of 1786 blood donors were screened for the presence of anti-hepatitis A antibody (anti HAV). 64.5% of the donors were found to be positive. The prevalence of the antibody was found to be age-related, 55% at 18 years and 75% at 65 years. No relationship was noted between the presence of antibody, foreign travel or a specific destination. Assay of antibody levels in selected seropositive individuals gave a mean level of 5.0 IU/ml. The prevalence of infection in this selected population is important in the context of passive immunization with normal human immunoglobulin and for defining a policy of immunization with hepatitis A vaccines, which are currently undergoing clinical trials.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553466      PMCID: PMC2249501          DOI: 10.1017/s0950268800030727

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  3 in total

1.  Hepatitis A immunity in British adults--an assessment of the need for pre-immunisation screening.

Authors:  R E Tettmar; R G Masterton; P W Strike
Journal:  J Infect       Date:  1987-07       Impact factor: 6.072

2.  Not all travellers need immunoglobulin for hepatitis A.

Authors:  J H Cossar; D Reid
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

3.  Increasing age--an important adverse prognostic factor in hepatitis A virus infection.

Authors:  A Forbes; R Williams
Journal:  J R Coll Physicians Lond       Date:  1988-10
  3 in total
  3 in total

1.  Notification of viral hepatitis.

Authors:  A J Zuckerman
Journal:  BMJ       Date:  1991-10-19

2.  Prevalence of hepatitis A antibodies in Swiss travellers.

Authors:  S Studer; H I Joller-Jemelka; R Steffen; P J Grob
Journal:  Eur J Epidemiol       Date:  1993-01       Impact factor: 8.082

3.  Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old.

Authors:  J Arístegui; J L Morales; R Dal-Ré; A González; M S Gallego; E Garrote
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.